Capital Wired

Keeps You Updated

Tuesday, January 19, 2021
Log in
  • Headlines
  • Business
  • Health
  • Tech & Science
  • Sports
  • World
  • US
  • Latest News
    • How To Make Your Own Home-Brewed Morphine
    • Using Mouthwash Too Often Puts You at Risk of Obesity and Diabetes
    • Walmart to Solve its Supply Chain Issues and Further Cut Down on Costs
    • The World’s Most Expensive Christmas Decorations
    • Netflix Hopes to Balance Data Limit With Great Video Quality
    • Joji Morishita says Japan Will Resume Whaling
    • The Most Beloved Plastic Surgeries Among Americans
    • Skype for Web Allows Non-Users to Take Part In Its Online Chats

Pages

  • About Capital Wired
  • Contact Us
  • Privacy Policy GDPR
  • Reprint & Licensing
  • Staff
  • Terms of Use

Recent Posts

  • Here’s Why Your Brain Keeps Worrying about Everything June 29, 2018
  • Don’t Throw That Sunscreen after Summer Is Up June 29, 2018
  • Analysts: Currency War between U.S. and China Might Be Looming June 28, 2018
  • Starbucks Rival The Coffee Bean & Tea Leaf Opening 100 Shops June 27, 2018
  • Study Finds We Are Alone in the Universe June 26, 2018
  • Restaurant Owner Not Sorry for Booting Sarah Sanders June 26, 2018
  • Beware of the Hidden Salt in Your Food! June 25, 2018

AbbVie Makes Massive $21 Billion Cancer Therapy Push

March 7, 2015 By Rebecca McGhee Leave a Comment

Email, RSS Follow

$21 Billion Cancer Therapy Push

AbbVie managed to win the bidding war that would decide the fate of PharmacyclicsInc. in a $21 billion deal that left Johnson & Johnsonoutside looking in on one of the most promising blood cancer therapies. The company’s newest cancer drug, Imbruvica, is expected to become a top-selling compound for the treatment of various cancer types. Novartis also expressed interest in Pharmacyclics’ product.

Imbruvica, Pharmacyclics’s flagship product, has received approval in more than 40 countries and is currently being used in the treatment of various cancer types, from leukemia to rare forms of lymphoma. As Pharmacyclics’s reports show, the drug already generated over $540 million in revenue in 2014 and experts believe that the drug would continue its growth trend this year.

The details of the transaction state that AbbVie will pay a whopping $261.25 per share, a 39 percent increase from what Pharmacyclics’s closing share price had been on February 24th, when the company had announced they were considering a deal. The price, according to the transaction terms, would be comprised of both cash and AbbVie equity.

“The acquisition of Pharmacyclics is a strategically compelling opportunity,”

Richard Gonzalez, AbbVie chairman and CEO said during a statement.

And while the opportunity would allow AbbVie to improve its position as an active player when it comes to cancer treatments, as the drug proved to not only be clinically efficient but has also raised care standards for oncologic patients, the company is surely also pleased to no longer have to rely solely on Humira, its best-selling rheumatoid arthritis compound.

Imbruvica comes in the form of an oral pill and represents a $100,000 yearly cost for patients and their healthcare insurers. With such figures, AbbVie could be looking at annual sales of over $3 billion within the following three years.

“[Imbruvica] is the only therapy to have received three breakthrough therapy designations by the FDA,”

AbbVie officials said when during the statement meant to announce the deal it had made with Pharmacyclics, a company that had an$86 million net income in 2014.

It’s true that some analysts fear that the newly acquired drug will most likely overlap with AbbVie’s ABT-199, a top pipeline oncology product, the company is certain that neither drug will interfere with the other’s performance.  In fact, Bloomberg analyst AsthikaGoonewardene believes that having two dogs in the race could only work in AbbVie’s benefit.

Close to mid-year, 58% of the deal should be already paid (in cash) while the remaining 42% are due in stock, AbbVie said.

<strong>Image Source: </strong><a href=”http://www.nationallawjournal.com/image/EM/Abbvie-Article-201410311310.jpg” target=”_blank” rel=”nofollow”>National Law Journal</a>

Email, RSS Follow

Rebecca McGhee

Rebecca McGhee is a valuable contributor for several publications and online platforms. Having graduates with a degree in Computer Science, her interest lies mostly in this area. Yet, she finds any tech-related topic or scientific topic is a challenge worth meeting. She enjoys turning her own research projects in worthy contributions that reach the large public. And mostly, she is grateful for all the feedback she receives from readers, as she believes it aids her in permanently improving her style of writing, beyond the scientific style she is accustomed to.

Filed Under: Business, Headlines

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Recent Articles

dc logo on black galaxy background

Ava DuVernay to Direct DC’s New Gods Adaptation

March 16, 2018 By Rebecca McGhee Leave a Comment

leonardo davinci's signature in black

Is DaVinci’s Record Breaking Painting Authentic?

November 20, 2017 By Rebecca McGhee Leave a Comment

stephen hawking

Stephen Hawking Makes Gloomy Prediction For Earth In A 100 Years

May 7, 2017 By Deborah Nielsen Leave a Comment

"Dwayne Johnson not dead"

Dwayne Johnson Died this Week or Not

January 19, 2016 By Jason Leathers 3 Comments

There Are At Least Three More Seasons of Game of Thrones To Go

July 31, 2015 By Rebecca McGhee Leave a Comment

Homelessness Soars in L.A., Officials Pledge to House Everybody by 2016

May 12, 2015 By Brian Galloway Leave a Comment

FBI Releases National Report on Slain Police Officers, Figures are Alarming

May 12, 2015 By Rebecca McGhee Leave a Comment

New York Nuclear Plant Partially Shut Down due to Hudson Oil Slick

May 11, 2015 By Jason Leathers 2 Comments

Obama Draws Heat from Democrats over Asia Trade Deal

May 9, 2015 By Rebecca McGhee Leave a Comment

Florida Governor Changes Stance on Obamacare Once More, Budget on Hold

May 9, 2015 By Brian Galloway Leave a Comment

Secret Service to add an Extra Layer of Spikes to White House Fence

May 8, 2015 By Chen Lai Leave a Comment

Police Arrested Suspect in death of Student who tried to Sell Car on Craigslist

May 8, 2015 By Deborah Nielsen 1 Comment

AccuWeather.com: 2015 Atlantic Tropical Storm Season is Officially Open

May 7, 2015 By Deborah Nielsen Leave a Comment

Illinois Student Found Dead after Trying to Sell his Car on Craigslist

May 7, 2015 By Deborah Nielsen 2 Comments

Related Articles

  • The Coffee Bean & Tea Leaf coffee shop

    Starbucks Rival The Coffee Bean & Tea Leaf Opening 100 Shops

    Jun 27, 2018
  • People dating online

    Tinder’s Parent Company Buying Sizable Stake in Tinder Rival

    Jun 21, 2018
  • Walmart store

    Arizona Man’s Fake Returns Cost Walmart $1.3M

    Jun 18, 2018
  • Google office in Spain

    Hispanic and Black Workers More Likely to Leave Google

    Jun 15, 2018
  • Amazon headquarters

    Seattle Backpedaling on ‘Head Tax’ amid Amazon Pressure

    Jun 12, 2018
  • North Korea lead Kim Jong-un

    North Korea Could Turn to Cryptocurrencies to Fend Off Sanctions

    Jun 6, 2018
  • Seattle skyline

    Seattle Passes Controversial Head Tax on Companies Making 20M/Year

    May 17, 2018
  • Call blocker

    FCC Hands Out Its Biggest Robocalling Fine to Date

    May 11, 2018
  • French flag blowing in the wind.

    California Man Fighting France over ‘France.com’ Domain

    Apr 30, 2018
  • Subway restaurant

    Subway Shutting Down 500 More Locations in the U.S.

    Apr 26, 2018

Categories

  • Business
  • Headlines
  • Health
  • Sports
  • Tech & Science
  • US
  • World

Copyright © 2021 capitalwired.com

About · Privacy Policy · Terms of Use · Contact

This website uses cookies to ensure you get the best experience on our website. Learn more.